Press releases

Japanese patients now have access to second-generation drug-eluting stent

Joel Fleishman to retire from Board

Adjustments reflected in the Company's Form 10-K to be filed tomorrow

Data show comparable safety for complex patients treated with TAXUS® Express2™ Stents and bypass surgery

Journal of American College of Cardiology publishes positive ATLAS clinical data

PLATINUM clinical program to evaluate PROMUS™ Element™ Platinum Chromium Stent

Q4 adjusted results in line with expectations; Company well positioned for 2009 and beyond

Product is Japan's first second-generation drug-eluting stent

Agreement stops all litigation in interventional cardiology and endovascular repair

Provides Company the opportunity to supply therapies for VA patients at risk of sudden cardiac death and bradycardia arrhythmias

Court found patent to be invalid as obvious over the prior art; Company considering its options for challenging the decision

Company will webcast its January 29 conference call

A live webcast of the January 14 presentation will be available

Acquisition demonstrates Company's commitment to innovation in drug-eluting stent technology

First patient enrolled in Carotid WALLSTENT® Endoprosthesis registry

First low-profile, pre-mounted stent approved specifically for use in renal arteries

A live webcast of the December 2, 2008 session will be available

New design provides more options for treating patients with complex lesions

Boston Scientific Corporation (NYSE: BSX) today welcomed passage of legislation to help active members of the U.S. armed forces and service...

Confirms clinical value and cost-effectiveness of spinal cord stimulation

Leading carotid stent in Europe and other international markets now available in the United States

"For the second consecutive quarter, we maintained our strong U.S. DES market share leadership," said President and CEO Jim Tobin

Landmark trial provides new insight for physicians

Outcomes from the study of 22,000 patients with coronary artery disease continues to show impressive safety and efficacy data

New SYNTAX Score shows similar safety and efficacy outcomes for two thirds of study's patients